Full Year 2024 Glenmark Life Sciences Ltd Earnings Call Transcript
Key Points
- Completion of the deal with Nirma Limited, providing increased growth capital.
- Secured business with Glenmark Pharma through a five-year master supply agreement.
- Gross margins remained strong at 56.1% for FY24, up from 53.1% in FY23.
- CDMO segment showed steady growth with expectations for commercialization of new products in H2 FY25.
- Strong order book and promising demand environment for the coming quarters.
- Geopolitical issues and Red Sea crisis caused significant supply chain disruptions, delaying shipments and inflating costs.
- Q4 revenue was impacted due to delayed flight availability and alignment with Nirma policies.
- Anticipated annual reduction in margins of 100 to 150 basis points due to the discontinuation of PLI scheme benefits.
- Higher employee costs due to a one-time bonus linked to management's past performance.
- Japan market experienced significant inventory destocking, impacting overall growth.
Ladies and gentlemen, good day, and welcome to Glenmark Life Sciences Limited Q4 FY24 earnings conference call. (Operator Instructions)Please note that this conference is being recorded. I now hand the conference over to Ms. Soumi Rao, General Manager of Corporate Communications and CSR. Thank you, and over to you.
Thank you, Neerav, and good evening, everyone. I welcome you all to the Earnings Call of Glenmark Life Sciences Limited for the quarter ended March 31, 2024 from Glenmark Life Sciences. Today we have with us Dr. Yasir Rawjee, our Managing Director and CEO of our Board, has approved the results for the quarter ended March 31, 2024 the release of, the same to the stock exchanges and updated it on our website. Please note that the recording and the transcript of this call will be available on the website of the company.
Now I'd like to draw your attention to the fact that some of the information shared as part of this call specially information with
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
